journal
MENU ▼
Read by QxMD icon Read
search

Clinical Breast Cancer

journal
https://www.readbyqxmd.com/read/28438672/the-management-strategy-of-benign-solitary-intraductal-papilloma-on-breast-core-biopsy
#1
Dayoung Ko, Eunyoung Kang, So Yeon Park, Sun Mi Kim, Mijung Jang, Bo La Yun, Sumin Chae, Yerang Jang, Hye Jin Kim, Sung-Won Kim, Eun-Kyu Kim
BACKGROUND: Intraductal papilloma (IDP) is well-known as one of the common benign breast lesions requiring excision. However, treatment of IDP without atypia is controversial. The aim of our study was to determine the proper management of solitary IDP by core needle biopsy (CNB). PATIENTS AND METHODS: We retrospectively reviewed patients with solitary IDP confirmed by CNB from March 2003 to March 2015. We collected data about final pathology after excision, as well as clinical, histologic, and radiologic findings at initial diagnosis...
April 1, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28433540/er-%C3%AE-36-interactions-with-cytosolic-molecular-network-in-acquired-tamoxifen-resistance
#2
REVIEW
Azin Teymourzadeh, Sepideh Mansouri, Leila Farahmand, Aysooda Hosseinzade, Keivan Majidzadeh-A
According to the World Health Organization (WHO) published data in 2015; breast cancer is the most prevalent and the second leading cause of cancer death among females. As approximately 70% of breast cancer tumor cells are estrogen receptor (ER) positive, primary therapeutic agents such as Anti-estrogens were produced mostly in a way to target this receptor. Anti-estrogen therapies mostly target Estrogen receptor and block its underlying signaling pathways. Nevertheless, resistance to these agents made the condition more complicated...
March 30, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28433541/the-impact-of-2013-updated-asco-cap-her2-guidelines-on-the-diagnosis-and-management-of-invasive-breast-cancer-a-single-center-study-of-1739-cases
#3
Xiaofei Zhang, Ira Bleiweiss, Shabnam Jaffer, Anupma Nayak
BACKGROUND: The purpose of this study was to determine the impact of revised ASCO/CAP 2013 HER2 guidelines on the clinical practice of pathologists and oncologists. MATERIALS AND METHODS: Retrospective analysis of 1739 patients with invasive breast carcinoma who underwent reflex HER2 (fluorescence in situ hybridization [FISH]) testing, using both 2007 and 2013 guidelines (2007-2014). RESULTS: Using 2013 guidelines, 255 (15%; 95% confidence interval [CI], 13%-16%) cases were classified as HER2(+) as opposed to 186 (11%; 95% CI, 9%-12%) by 2007 guidelines (odds ratio [OR] 1...
March 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28412326/no-acute-changes-in-lvef-observed-with-concurrent-trastuzumab-and-breast-radiation-with-low-heart-doses
#4
Shelly X Bian, Mariam P Korah, Taylor R Whitaker, Lingyun Ji, Susan Groshen, Eugene Chung
INTRODUCTION/BACKGROUND: Treatment for HER2-postitive breast cancer often includes trastuzumab, breast/chest wall (CW) radiation (RT), and anthracyclines, all of which have cardiac toxicity. We aimed to evaluate the relationship between heart dose and acute left ventricular ejection fraction (LVEF) changes in patients who received concurrent trastuzumab and breast/CW RT with and without anthracycline use. PATIENTS AND METHODS: We retrospectively reviewed all nonmetastatic breast cancer patients from 2008 to 2015 who received concurrent trastuzumab and breast/CW RT...
March 23, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28416193/lep-rs7799039-lepr-rs1137101-and-adipoq-rs2241766-and-1501299-polymorphisms-are-associated-with-obesity-and-chemotherapy-response-in-mexican-women-with-breast-cancer
#5
Alejandra Méndez-Hernández, Martha Patricia Gallegos-Arreola, Hortensia Moreno-Macías, Jorge Espinosa Fematt, Rebeca Pérez-Morales
BACKGROUND: Obesity plays a major role in the pathogenesis of breast cancer. Leptin (LEP) and adiponectin (ADIPOQ) are important in the regulation of adipose tissue. The response to cancer treatment depends on the histological and molecular tumor type, clinical stage, and genetic variability that might promote carcinogenic development. The aim of this study was to investigate the association between overweight/obesity and polymorphisms in the LEP (rs7799039), LEP receptor (LEPR; rs1137101), and ADIPOQ genes (rs2241766, rs1501299) with the response to breast cancer treatment in Mexican women...
March 22, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28420584/neuroendocrine-carcinoma-of-the-breast-with-endobronchial-metastases-and-syndrome-of-inappropriate-antidiuretic-hormone-secretion
#6
Anaum Maqsood, Thaer Khoury, Prasanna Kumar, Antonios Papanicolau-Sengos, Amy P Early
No abstract text is available yet for this article.
March 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28410844/folate-receptor-alpha-expression-is-associated-with-increased-risk-of-recurrence-in-triple-negative-breast-cancer
#7
Paula S Ginter, Patrick J McIntire, Xiaoyan Cui, Lina Irshaid, Yifang Liu, Zhengming Chen, Sandra J Shin
BACKGROUND: Folate receptor alpha (FOLR1) has been identified as a potential prognostic and therapeutic target in breast cancer. The limited studies evaluating the role of FOLR1 in breast cancer have shown that FOLR1 protein expression is enriched in triple-negative breast cancer (TNBC) and associated with poor prognosis in all breast cancer types. Newly developed anti-FOLR1 therapy could potentially be used in patients with TNBC for whom few therapeutic options exist. We sought to evaluate FOLR1 protein expression in a cohort of patients with TNBC to determine its prevalence and prognostic value...
March 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28396099/management-of-isolated-locoregional-recurrences%C3%A2-in-breast-cancer-a-review-of-local%C3%A2-and-systemic-modalities
#8
REVIEW
Tabassum Wadasadawala, Rohit Vadgaonkar, Jyoti Bajpai
Locoregional recurrence (LRR) after adequate treatment of primary breast cancer poses a therapeutic challenge. Advances in the management of breast cancer have led to significant improvements in survival. With this advantage, it is observed that the incidence of LRR has relatively decreased. Systemic involvement should be ruled out in patients presenting with locoregionally recurrent disease, as isolated LRR requires a treatment with curative intent. Salvage mastectomy following ipsilateral breast tumor recurrence is a time-tested treatment option and widely accepted...
March 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28385537/phase-i-trial-of-everolimus-and-capecitabine-in-metastatic-her2-breast-cancer
#9
Gregory A Vidal, Mary Chen, Shruti Sheth, Tiffany Svahn, Ellie Guardino
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is a driver of breast tumorigenesis. The mTOR inhibitor everolimus reverses antihormonal therapy resistance and is an approved therapy for metastatic breast cancer. A synergistic effect with fluoropyrimidine has been suggested. The present study evaluated the safety and tolerability of an all-oral combination of everolimus and capecitabine for metastatic breast cancer (MBC). PATIENTS AND METHODS: MBC patients naive to capecitabine and mTOR inhibitors who had received ≤ 3 previous chemotherapy regimens in the metastatic setting were eligible for the present study...
March 16, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28365336/associations-between-patient-and-anthropometric-characteristics-and-aromatase-inhibitor-discontinuation
#10
N Lynn Henry, Kelly Speth, Anneleen Lintermans, Kelley M Kidwell, Rachel Carlson, Daniel F Hayes, Patrick Neven
BACKGROUND: Toxicity can lead to noncontinuation of adjuvant endocrine therapy. We hypothesized that endocrine therapy-induced changes in grip strength would predict for early discontinuation of therapy because of musculoskeletal toxicity and would be associated with a patient's body mass index. PATIENTS AND METHODS: Postmenopausal women with breast cancer starting a new adjuvant endocrine therapy were enrolled in the present study. The patients were monitored for 12 months to assess their symptoms, endocrine therapy adherence and change in grip strength and baseline body mass index...
March 11, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28366406/nab-paclitaxel-in-advanced-her2-negative-breast-cancer-patients-efficacy-and-safety-beyond-clinical-trials
#11
Antonio Bernardo, Raffaella Palumbo, Rebecca Pedersini, Elena Rota Caremoli, Anna Rita Gambaro, Antonella Ferzi, Francesca Riva, Donatella Grasso, Marco Danova, Emiliana Tarenzi, Valter Torri, Marina E Cazzaniga
BACKGROUND: Few data are available regarding efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel in advanced breast cancer patients outside a controlled trial, especially for the weekly schedule. PATIENTS AND METHODS: We prospectively collected data of advanced breast cancer patients who were candidates to be treated with weekly (125 mg/m(2) for 3 consecutive weeks followed by a 1-week rest) or every 3 weeks (260 mg/m(2)) schedules of nab-paclitaxel, according to physician's decision...
March 9, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28359730/the-changing-role-of-vacuum-assisted-biopsy-of-the-breast-a-new-prototype-of-minimally-invasive-breast-surgery
#12
Ian C Bennett
No abstract text is available yet for this article.
March 9, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28342776/effect-of-needle-size-in-ultrasound-guided-core-needle-breast-biopsy-comparison-of-14-16-and-18-gauge-needles
#13
Michela Giuliani, Pierluigi Rinaldi, Rossella Rella, Gina Fabrizi, Federica Petta, Giorgio Carlino, Alba Di Leone, Antonino Mulè, Enida Bufi, Maurizio Romani, Paolo Belli, Lorenzo Bonomo
INTRODUCTION: The aim of the present study was to assess the diagnostic accuracy of ultrasound-guided core needle biopsy (US-CNB) of breast lesions, comparing smaller needles (16- and 18-gauge) with the 14-gauge needle, and to analyze the lesion characteristics influencing US-CNB diagnostic performance. PATIENTS AND METHODS: All the patients provided informed consent before the biopsy procedure. The data from breast lesions that had undergone US-CNB in our institution from January 2011 to January 2015 were retrospectively reviewed...
March 6, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28365334/can-locoregionally-recurrent-breast-cancer-be-cured
#14
REVIEW
Arati Rani Chand, M Firdos Ziauddin, Shou-Ching Tang
Locoregional recurrence (LRR) of breast cancer can occur after multidisciplinary treatment of a primary breast cancer. With modern multidisciplinary breast cancer treatment, the incidence of isolated LRR is decreasing. Improvements in systemic therapy are driving the decrease in LRR. LRR does still occur, however. LRR reflects biology of the cancer, as does systemic recurrence. LRR of breast cancer is frequently associated with systemic disease recurrence and poor prognosis. Given this associated poor prognosis, historically, it has been unclear whether patients with LRR would benefit from aggressive therapy with curative intent...
March 2, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28284904/flap-fixation-using-tissue-glue-or-sutures-after-mastectomy-might-also-reduce-risk-of-developing-lymphedema-in-breast-cancer
#15
LETTER
Kadri Altundag
No abstract text is available yet for this article.
February 20, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28336245/does-the-timing-of-chemotherapy-affect-post-mastectomy-breast-reconstruction-complications
#16
Oriana Cohen, Gretl Lam, Mihye Choi, Nolan Karp, Daniel Ceradini
INTRODUCTION: In this study we evaluated how the timing of chemotherapy for breast cancer affects post-reconstruction complications to determine whether there is an optimal time for breast reconstruction after chemotherapy. PATIENTS AND METHODS: A retrospective review identified 344 breast cancer patients who underwent chemotherapy with mastectomy and autologous/prosthetic reconstruction from 2011 to 2014. A control group of 127 breast cancer patients who underwent mastectomy and autologous/prosthetic reconstruction without chemotherapy was also identified from the same period...
February 17, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28283437/molecular-subtypes-and-lower-inner-quadrant-tumors-in-breast-cancer-debate-is-still-ongoing
#17
LETTER
Kadri Altundag
No abstract text is available yet for this article.
February 17, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28347604/the-prognostic-value-of-her2-positive-circulating-tumor-cells-in-breast-cancer-patients-a-systematic-review-and-meta-analysis
#18
Cheng-Hsu Wang, Chee-Jen Chang, Kun-Yun Yeh, Pei-Hung Chang, Jen-Seng Huang
INTRODUCTION: A meta-analysis was conducted to determine the prognostic value of HER2-positive circulating tumor cells (CTCs) in patients with breast cancer. MATERIALS AND METHODS: MedLine, Central, and Embase databases were searched. Inclusion criteria were: (1) randomized controlled trials, 2-arm prospective studies, and retrospective studies; (2) patients with breast cancer; (3) HER2-positive CTCs were examined; and (4) hazard ratio (HR) of survival between patients with HER2-positive and HER2-negative CTCs was reported...
February 16, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28330681/can-mthfr-c677t-and-a1298c-polymorphisms-alter-the-risk-and-severity-of-sporadic-breast-cancer-in-brazilian-women
#19
Luciana Montes Rezende, Fernando Augusto Lima Marson, Carmen Sílvia Passos Lima, Carmen Sílvia Bertuzzo
INTRODUCTION: Polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) modify the risk and severity of sporadic breast cancer (BC). In this context, the MTHFR C677T and A1298C polymorphisms have been associated with risk and severity of sporadic BC. PATIENTS AND METHODS: In total, 253 women with BC and 257 controls were enrolled in this study. Polymorphisms were analyzed using restriction fragment length polymorphism - polymerase chain reaction. Epidemiology, tumor characteristics, and reproductive factors were considered in the analysis...
February 16, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28428099/nipple-sparing-mastectomy-and-its-application-on-brca-gene-mutation-carrier
#20
REVIEW
Michael Co, Rosemarie Chiu, Tung Milly Chiu, Yau Chun Chong, Swan Lau, Yung Ho Lee, Hoi Man To, Ava Kwong
In breast cancer 1 (BRCA) gene mutation carriers, mastectomy is still the mainstay of treatment for breast cancers due to the increased risk of local recurrence. It is performed as a therapeutic, as well as prophylactic procedure. However, mastectomy with removal of nipple areolar complex (NAC) is associated with adverse cosmetic outcome. NAC sparing mastectomy (NSM), which results in better cosmetic outcome, has been performed in non-BRCA mutation carriers. While studies have shown that NSM is a oncologically safe in sporadic breast cancers, its application in BRCA mutation carriers is still controversial...
February 14, 2017: Clinical Breast Cancer
journal
journal
34827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"